LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $9.00

LifeStance Health Group (NASDAQ:LFST) had its target price boosted by UBS Group from $8.50 to $9.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, BTIG Research started coverage on shares of LifeStance Health Group in a research report on Friday, July 25th. They set a “buy” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $4.37 on Friday. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.61. The firm’s 50 day moving average is $4.77 and its 200-day moving average is $6.17. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -87.40 and a beta of 1.13. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.12%. The company had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. During the same period in the prior year, the business earned ($0.06) earnings per share. LifeStance Health Group’s quarterly revenue was up 10.6% on a year-over-year basis. Sell-side analysts forecast that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ujjwal Ramtekkar sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total value of $95,040.00. Following the completion of the sale, the insider owned 113,435 shares of the company’s stock, valued at approximately $673,803.90. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several large investors have recently bought and sold shares of the company. DekaBank Deutsche Girozentrale bought a new stake in shares of LifeStance Health Group during the first quarter worth $31,000. Park Edge Advisors LLC bought a new stake in shares of LifeStance Health Group during the second quarter worth $52,000. Xponance Inc. bought a new stake in shares of LifeStance Health Group during the first quarter worth $69,000. Public Employees Retirement System of Ohio acquired a new position in LifeStance Health Group during the second quarter worth $70,000. Finally, Blair William & Co. IL acquired a new position in LifeStance Health Group during the second quarter worth $70,000. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.